{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8"},{"groupId":"OG001","value":"18.5"}]}],"title":"Good Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5"},{"groupId":"OG001","value":"42.7"}]}],"title":"Moderate Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \\< -1.2 was a good response, \\< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \\> 3.2 to ≤ 5.1, a change from baseline of \\< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \\> 5.1, a change from baseline \\< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \\> 3.2.","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Retreatment"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population includes all participants randomized to Retreatment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Percentage of Retreated Subjects With a European League Against Rheumatism (EULAR) Response at Week 48","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}